Holen Sie sich die Stockscreener-App
12.02
2.39%
0.28
Handel nachbörslich:
11.91
-0.11
-0.92%
Schlusskurs vom Vortag:
$11.74
Offen:
$11.75
24-Stunden-Volumen:
5.45M
Relative Volume:
0.82
Marktkapitalisierung:
$1.39B
Einnahmen:
$52.86M
Nettoeinkommen (Verlust:
$-480.19M
KGV:
-2.563
EPS:
-4.6899
Netto-Cashflow:
$-421.82M
1W Leistung:
+18.66%
1M Leistung:
+33.26%
6M Leistung:
+0.59%
1J Leistung:
+23.47%
1-Tages-Spanne:
$11.66
$12.34
1-Wochen-Bereich:
$10.13
$12.34
52-Wochen-Spanne:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
12.02 | 1.36B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.53 | 115.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.14 | 79.76B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
799.33 | 50.16B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
366.86 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.75 | 38.85B | 4.98B | 69.59M | 525.67M | 0.5197 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average - Yahoo Finance
SG Americas Securities LLC Acquires 92,485 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
ARK Investment Increases Stake in Intellia Therapeutics (NTLA) - GuruFocus
cathie wood’s ARK stock buys INTELLIA, continues trend By Investing.com - Investing.com Nigeria
cathie wood’s ARK stock buys INTELLIA, continues trend - Investing.com
Intellia Therapeutics (NASDAQ:NTLA) Trading Up 6.9%Still a Buy? - MarketBeat
cathie wood’s ARK stock trades highlight intellia, personalis buys By Investing.com - Investing.com Australia
Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Roche Holding AG (RHHVF) - The Globe and Mail
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares - sharewise.com
Fred Cohen Buys 303% More Intellia Therapeutics Shares - Yahoo Finance
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina By Investing.com - Investing.com Canada
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina - Investing.com
Intellia Updates Investors on Nex-Z Trial Safety Hold - TipRanks
Intellia Therapeutics, Inc. Updates on Clinical Trials and Regulatory Plans - TradingView — Track All Markets
Why Intellia Therapeutics Inc. (38I) stock fits value portfoliosMarket Movement Recap & AI Optimized Trade Strategies - ulpravda.ru
CEO Change: Is Intellia Therapeutics Inc. stock a defensive play in 2025Wall Street Watch & Safe Capital Allocation Plans - ulpravda.ru
How Intellia Therapeutics Inc. stock benefits from global expansion2025 Earnings Surprises & Safe Swing Trade Setups - ulpravda.ru
Buyback Watch: Can Intellia Therapeutics Inc. stock beat market expectations this quarterWeekly Trend Report & Free Long-Term Investment Growth Plans - ulpravda.ru
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap UpTime to Buy? - MarketBeat
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Insider Buying: Fred Cohen Acquires 150,000 Shares of Intellia T - GuruFocus
Intellia Therapeutics Insider Sold Shares Worth $314,485, According to a Recent SEC Filing - marketscreener.com
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Intellia Therapeutics
Intellia Therapeutics prepares for JPM Healthcare Conference presentation - Traders Union
44th Annual J.P. Morgan Healthcare Conference - Intellia Therapeutics
Gene editing firm Intellia to share CRISPR work at major health event - Stock Titan
What analysts say about Intellia Therapeutics Inc 38I stockUtilities Sector Analysis & Identify Ideal Buy Points With Precision - earlytimes.in
Why Intellia Therapeutics (NTLA) Is Down After FDA Halts Key CRISPR Trial Over Safety Concerns – And What's Next - Sahm
BofA Adjusts Price Target on Intellia Therapeutics to $12 From $14, Maintains Neutral Rating - marketscreener.com
Intellia Stock Declines Around 55% in 3 Months: Here's Why - Finviz
Intellia Therapeutics reports inducement grants - Medical Buyer
We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully - Yahoo Finance
Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aug Big Picture: Can Intellia Therapeutics Inc stock beat analyst upgradesJuly 2025 Momentum & Daily Technical Stock Forecast Reports - moha.gov.vn
Trading the Move, Not the Narrative: (NTLA) Edition - Stock Traders Daily
Short Squeeze: Is Intellia Therapeutics Inc stock a defensive play in 20252025 Support & Resistance & Real-Time Chart Breakout Alerts - moha.gov.vn
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga
Cathie Wood shells out $1.3 million on biotech stock - Yahoo Finance
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab - Yahoo Finance
Cathie Wood’s ARK makes strategic stock moves, buys Intellia and sells Roku By Investing.com - Investing.com South Africa
Cathie Wood’s ARK makes strategic stock moves, buys Intellia and sells Roku - Investing.com
What makes Intellia Therapeutics (NTLA) an interesting investment? - MSN
What Makes Intellia Therapeutics (NTLA) an Interesting Investment? - Finviz
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street - Finviz
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN
Voya Investment Management LLC Trims Stock Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Intellia Therapeutics (NASDAQ:NTLA) Cut to "Sell" at Wall Street Zen - MarketBeat
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.44%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):